Foundry Healthcare Short-Term Reversal Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1ISRG | INTUITIVE SURGICAL INC | Healthcare | $122.33B | 36.92% |
2ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 10.78% |
3MRNA | MODERNA INC | Healthcare | $24.53B | 7.40% |
4ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 3.16% |
5TEM | TEMPUS AI INC | Healthcare | $9.42B | 2.84% |
6IONS | IONIS PHARMACEUTICALS INC | Healthcare | $8.99B | 2.71% |
7IBRX | IMMUNITYBIO INC | Healthcare | $8.04B | 2.43% |
8TWST | TWIST BIOSCIENCE CORP | Healthcare | $5.84B | 1.76% |
9MANE | VERADERMICS INC | Healthcare | $4.65B | 1.40% |
10CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.61B | 1.39% |
11CELC | CELCUITY INC | Healthcare | $4.31B | 1.30% |
12ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $4.26B | 1.29% |
13TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.13B | 1.25% |
14DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.70B | 1.12% |
15GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $3.45B | 1.04% |
16RCUS | ARCUS BIOSCIENCES INC | Healthcare | $3.44B | 1.04% |
17WRBY | WARBY PARKER INC | Healthcare | $3.24B | 0.98% |
18RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 0.87% |
19BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.83B | 0.85% |
20VERA | VERA THERAPEUTICS INC | Healthcare | $2.76B | 0.83% |
21QURE | UNIQURE NV | Healthcare | $2.54B | 0.77% |
22SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $2.45B | 0.74% |
23KLRA | KAILERA THERAPEUTICS INC | Healthcare | $2.40B | 0.73% |
24HTFL | HEARTFLOW INC | Healthcare | $2.15B | 0.65% |
25AXGN | AXOGEN INC | Healthcare | $2.12B | 0.64% |
26ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 0.60% |
27OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.96B | 0.59% |
28UFPT | UFP TECHNOLOGIES INC | Healthcare | $1.87B | 0.57% |
29STOK | STOKE THERAPEUTICS INC | Healthcare | $1.81B | 0.55% |
30GENB | GENERATE BIOMEDICINES INC | Healthcare | $1.74B | 0.52% |
31BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.73B | 0.52% |
32TSHA | TAYSHA GENE THERAPIES INC | Healthcare | $1.71B | 0.52% |
33ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.51% |
34CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.67B | 0.50% |
35NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.48% |
36NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.41% |
37AKTS | AKTIS ONCOLOGY INC | Healthcare | $1.33B | 0.40% |
38STAA | STAAR SURGICAL CO | Healthcare | $1.32B | 0.40% |
39ABSI | ABSCI CORP | Healthcare | $1.29B | 0.39% |
40INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.39% |
41AVLN | AVALYN PHARMA INC | Healthcare | $1.25B | 0.38% |
42MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.35% |
43SVRA | SAVARA INC | Healthcare | $1.13B | 0.34% |
44CAPR | CAPRICOR THERAPEUTICS INC | Healthcare | $1.13B | 0.34% |
45PRCT | PROCEPT BIOROBOTICS CORP | Healthcare | $1.09B | 0.33% |
46OLMA | OLEMA PHARMACEUTICALS INC | Healthcare | $1.00B | 0.30% |
47REPL | REPLIMUNE GROUP INC | Healthcare | $859M | 0.26% |
48SLDB | SOLID BIOSCIENCES INC | Healthcare | $859M | 0.26% |
49AVR | ANTERIS TECHNOLOGIES GLOBAL CORP | Healthcare | $823M | 0.25% |
50DSGN | DESIGN THERAPEUTICS INC | Healthcare | $785M | 0.24% |
51ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $755M | 0.23% |
52GMRS | GMR SOLUTIONS INC | Healthcare | $721M | 0.22% |
53SPRY | ARS PHARMACEUTICALS INC | Healthcare | $695M | 0.21% |
54SGP | SPYGLASS PHARMA INC | Healthcare | $661M | 0.20% |
55GYRE | GYRE THERAPEUTICS INC | Healthcare | $587M | 0.18% |
56FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.17% |
57RLMD | RELMADA THERAPEUTICS INC | Healthcare | $550M | 0.17% |
58CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $532M | 0.16% |
59EIKN | EIKON THERAPEUTICS INC | Healthcare | $529M | 0.16% |
60CTEV | CLARITEV CORP | Healthcare | $518M | 0.16% |
61ZURA | ZURA BIO LTD | Healthcare | $518M | 0.16% |
62DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.16% |
63RGNX | REGENXBIO INC | Healthcare | $511M | 0.15% |
64CLPT | CLEARPOINT NEURO INC | Healthcare | $454M | 0.14% |
65PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.14% |
66KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $453M | 0.14% |
67EVMN | EVOMMUNE INC | Healthcare | $437M | 0.13% |
68CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.12% |
69MOBI | MOBIA MEDICAL INC | Healthcare | $404M | 0.12% |
70EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.12% |
71STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.12% |
72EOLS | EVOLUS INC | Healthcare | $377M | 0.11% |
73CV | CAPSOVISION INC | Healthcare | $335M | 0.10% |
74VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.10% |
75MASS | 908 DEVICES INC | Healthcare | $278M | 0.08% |
76CNXU | CONEXEU SCIENCES INC | Healthcare | $263M | 0.08% |
77ZSQR | Z SQUARED INC | Healthcare | $260M | 0.08% |
78SRZN | SURROZEN INC | Healthcare | $255M | 0.08% |
79RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.07% |
80GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $240M | 0.07% |
81SENS | SENSEONICS HOLDINGS INC | Healthcare | $214M | 0.06% |
82RNA | ATRIUM THERAPEUTICS INC | Healthcare | $208M | 0.06% |
83BDSX | BIODESIX INC | Healthcare | $204M | 0.06% |
84ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.05% |
85LENZ | LENZ THERAPEUTICS INC | Healthcare | $162M | 0.05% |
86VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.04% |
87SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $120M | 0.04% |
88VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.03% |
89PARK | PARK DENTAL PARTNERS INC | Healthcare | $88M | 0.03% |
90NRXS | NEURAXIS INC | Healthcare | $84M | 0.03% |
91ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.02% |
92NMAD | NOMAD POWER SOLUTIONS INC | Healthcare | $72M | 0.02% |
93AGPU | AXE COMPUTE INC | Healthcare | $72M | 0.02% |
94LONA | LEONABIO INC | Healthcare | $68M | 0.02% |
95IMA | IMAGENEBIO INC | Healthcare | $61M | 0.02% |
96EDSA | EDESA BIOTECH INC | Healthcare | $59M | 0.02% |
97SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.02% |
98INKT | MINK THERAPEUTICS INC | Healthcare | $53M | 0.02% |
99MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.02% |
100EXOZ | EXOZYMES INC | Healthcare | $51M | 0.02% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $331.39B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 86% toward Large, 79% toward Growth. +10% unclassified (21 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 100 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual59.9%Margin-15.1%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual36.9%Margin-11.9%
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 100 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 17.8% | -22.2% |
| 3 yearsp.a. | -9.5% | -13.7% |
| 5 yearsp.a. | -17.0% | -20.7% |
| 10 yearsp.a. | 2.8% | -5.2% |
| Since inceptionp.a. | 8.2% | -0.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | -4.7% | -16.5% |
| 2025 | 0.2% | -13.8% |
| 2024 | -10.4% | 12.5% |
| 2023 | -3.2% | -27.2% |
| 2022 | -48.0% | -47.8% |
| 2021 | 20.7% | 37.0% |
| 2020 | 45.3% | 5.4% |
| 2019 | 25.1% | 12.2% |
| 2018 | 4.9% | 5.0% |
| 2017 | 35.1% | -3.7% |
| 2016 | -20.2% | 1.1% |
| 2015 | -12.3% | -15.5% |
| 2014 | 46.7% | 22.1% |
| 2013 | 49.7% | 5.5% |
| 2012 | 32.6% | 21.2% |
| 2011 | -0.5% | 0.5% |
| 2010 | 9.1% | -2.5% |
| 2009 | 55.8% | 41.4% |
| 2008 | -23.7% | 12.0% |
| 2007 | 3.7% | -12.1% |
| 2006 | 13.4% | 6.4% |
| 2005 | 0.5% | -9.8% |
| 2004 | 8.8% | 10.0% |
| 2003 | 48.1% | 4.5% |
| 2002 | -29.6% | 14.5% |
| 2001 | 22.5% | 44.5% |
| 2000 | 78.1% | -19.0% |
| 1999 | -15.0% | -35.4% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Short-Term Reversal Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Short-Term Reversal signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.